Icandra (previously Vildagliptin / metformin hydrochloride Novartis) Unió Europea - croat - EMA (European Medicines Agency)

icandra (previously vildagliptin / metformin hydrochloride novartis)

novartis europharm limited - вилдаглиптин, metformin hidroklorid - dijabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 i 5. 1 za dostupne podatke o različitim kombinacijama).

Imbruvica Unió Europea - croat - EMA (European Medicines Agency)

imbruvica

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Imlygic Unió Europea - croat - EMA (European Medicines Agency)

imlygic

amgen europe b.v. - talimogene laherparepvec - melanoma - antineoplastična sredstva - imlygic je indiciran za liječenje odraslih s inoperabilnim melanom koji je regionalno ili najudaljenijim metastatski (stage iiib, iiic i ivm1a) nema kosti, mozak, pluća ili drugih visceralne bolesti.

Imvanex Unió Europea - croat - EMA (European Medicines Agency)

imvanex

bavarian nordic a/s - modificirana vakcina ankara - bavarska nordijska (mva-bn) virus - smallpox vaccine; monkeypox virus - drugih virusnih cjepiva, - active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults (see sections 4. 4 i 5. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.

Incresync Unió Europea - croat - EMA (European Medicines Agency)

incresync

takeda pharma a/s - alogliptin, pioglitazone - dijabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - incresync is indicated as a second- or third-line treatment in adult patients aged 18 years and older with type-2 diabetes mellitus: , as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on pioglitazone alone, and for whom metformin is inappropriate due to contraindications or intolerance;, in combination with metformin (i. trostruka kombinirana terapija) kao dodatak prehrani i fizičke vježbe za poboljšanje glikemijski kontrole kod odraslih pacijenata (posebno u pacijenata s viškom težine) neadekvatna na njihovu maksimalnu переносимой doze метформина i пиоглитазона. osim toga , incresync može se koristiti kako bi zamijeniti pojedine tablete alogliptin i pioglitazone u onih odraslih pacijenata u dobi od 18 godina i stariji sa dm-2 već šećerna bolest liječi sa ovom kombinacijom. nakon početka terapije s incresync, pacijenti moraju biti revidiran nakon tri do šest mjeseci, za procjenu adekvatnosti odgovora na liječenje (e. smanjenje pokazatelja hba1c). kod bolesnika koji ne pokazuju adekvatan odgovor, incresync treba prestati. u svjetlu potencijalnih rizika kod duljeg pioglitazone terapija, propisane lijekove treba potvrditi u kasnijim rutinske inspekcije da dobro incresync sprema (vidi odjeljak 4.

Inlyta Unió Europea - croat - EMA (European Medicines Agency)

inlyta

pfizer europe ma eeig  - axitinib - karcinom, stanice bubrega - inhibitori протеинкиназы - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.

Instanyl Unió Europea - croat - EMA (European Medicines Agency)

instanyl

takeda pharma a/s - fentanil citrat - pain; cancer - analgetici - instanyl je indiciran za upravljanje probavnom boli kod odraslih koji već primaju opioidnu terapiju za kroničnu bol u raku. probijanje boli je prolazno pogoršanje boli koja se javlja na pozadini drugačije kontrolirane upornosti boli.  patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.

Panacur AquaSol Unió Europea - croat - EMA (European Medicines Agency)

panacur aquasol

intervet international bv - fenbendazol - Антгельминтики, , Бензимидазолы i srodnih tvari, фенбендазола - pigs; chicken - za liječenje probavnog sustava hookworms svinja zaraženo:аскарида АЧС (odrasla osoba, crijeva i migracija larvi stadija);oesophagostomum cse. (odrasli stadij);власоглавы суис (odrasli stadij). za liječenje probavnog sustava нематодозах pilića, zaražene:ascaridia galli l (l5 i odrasle);heterakis gallinarum (Л5 i odrasle);capillaria cse. (Л5 i odrasle osobe).

Invanz Unió Europea - croat - EMA (European Medicines Agency)

invanz

merck sharp & dohme b.v. - ertapenem natrij - community-acquired infections; streptococcal infections; staphylococcal infections; gram-negative bacterial infections; surgical wound infection; pneumonia, bacterial - antibakterijski lijekovi za sistemsku primjenu, - treatmenttreatment od sljedećih infekcija kada su uzrokovane bakterijama poznato ili s velikom vjerojatnošću će podložno эртапенем i kada парентеральной terapije potrebno je:интраабдоминальные infekcije;внебольничная upala pluća;akutne ginekološki bolesti;dijabetes i stopala infekcije kože i mekih tkiva. preventioninvanz navodi u odraslih za prevenciju kirurške infekcije nakon planske колоректальной kirurgija. treba uzeti u obzir formalne preporuke za odgovarajuće korištenje antibakterijskih posrednika.

Invega Unió Europea - croat - EMA (European Medicines Agency)

invega

janssen-cilag international nv - paliperidon - schizophrenia; psychotic disorders - psycholeptics - invega je indicirana za liječenje shizofrenije u odraslih i adolescenata od 15 godina i starije. Инвега namijenjen za liječenje шизоаффективного poremećaja kod odraslih.